SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
A Special Committee is conducting an ongoing strategic review evaluating financing, recapitalization, restructuring, M&A, and other strategic transactions, with engagement of major financial advisors (Houlihan Lokey and FTI Consulting) and active discussions with lenders regarding potential credit agreement amendments.
View raw filing on EDGAR →AmperCap Acquisition Company consummated its IPO on June 4, 2026, raising $125 million through the sale of 12.5 million units and entering into multiple material definitive agreements (underwriting, business combination marketing, private placement, and trust agreements) in connection with the offering.
View raw filing on EDGAR →AmperCap completed a private placement of 512,500 units at $10.00 per unit to the Sponsor, EBC, and third-party investors simultaneously with the IPO closing, issued pursuant to Section 4(a)(2) exemption from registration.
View raw filing on EDGAR →Three individuals—John Salemi, Luis Pena Kegel, and Alfredo Flores Ibarrola—were appointed to the board of directors effective June 2, 2026, in connection with the IPO, with each also appointed to the Audit Committee and Compensation Committee, and Salemi chairing both committees.
View raw filing on EDGAR →The filing discloses a material disposition of assets: VSee Health sold all equity securities of its wholly-owned subsidiary VSee Lab to Milton Chen (the co-CEO and Chairman) in exchange for Chen's transfer of 2,870,069 shares of common stock to the Company. This is a significant restructuring involving a change of control of a subsidiary and a material equity transaction, disclosed under Items 1.01 (Entry into Material Definitive Agreement), 2.01 (Completion of Acquisition or Disposition of Assets), and 3.02 (Unregistered Sales of Equity Securities). While an executive departure also occurs (Chen's resignation as co-CEO and Chairman), the central disclosed event is the asset disposition and equity swap transaction.
View raw filing on EDGAR →David Bailey, a co-founder and board member of RTB Digital, is departing the board of directors effective June 1, 2026, to focus on his CEO role at Nakamoto, Inc. The filing explicitly states his departure and notes he was a "founding investor and board member" who participated in recent funding rounds. While the departure is amicable and not due to disagreement, the loss of a founding board member who was actively involved in capital raises is material to investors' assessment of the company's governance and continuity.
View raw filing on EDGAR →This Item 3.02 disclosure reports an unregistered sale of 1,318,837.5608 common shares for $33.3 million in aggregate consideration, exempt under Section 4(a)(2) and Regulation D Rule 506. The sale includes multiple share classes (F-I, F-S, and E) sold to third-party investors and insiders. This is a classic dilutive equity issuance in a continuous private offering, material to investors assessing ownership dilution and capital raising activity.
View raw filing on EDGAR →Seadrill held its Annual General Meeting on June 3, 2026, at which shareholders voted on and approved six proposals: board size determination, re-election of nine directors, appointment of PwC US as auditor, director remuneration approval, advisory vote on named executive officer compensation, and Amendment No. 1 to the 2022 Management Incentive Plan.
View raw filing on EDGAR →This Item 5.07 filing discloses the final results of three shareholder votes at Zumiez's Annual Meeting: election of three directors (Thomas D. Campion, Liliana Gil Valletta, Carmen R. Bauza), an advisory vote on executive compensation, and ratification of Baker Tilly US, LLP as independent auditor. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →Seres Therapeutics amended its Asset Purchase Agreement with Société des Produits Nestlé S.A., materially restructuring contingent milestone payment obligations by terminating $125M and $150M future milestone payments in exchange for a $25M immediate payment. The company also amended its lease agreement, reducing square footage by approximately 55% and decreasing lease payments by $33.9M.
View raw filing on EDGAR →ABM Industries disclosed financial results for the quarter ended April 30, 2026, through a press release filed under Item 2.02.
View raw filing on EDGAR →This disclosure announces translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, an anti-APRIL monoclonal antibody candidate. The announcement includes positive preliminary safety findings (no serious adverse events, dose-limiting toxicities, or discontinuations in 49 healthy volunteers up to 320 mg) and supportive pharmacokinetic/pharmacodynamic modeling suggesting potential for less-frequent dosing. While this is a clinical development milestone for a pipeline asset, it does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation). The disclosure would be material to investors evaluating the company's pipeline progress and risk profile, particularly given the positive safety profile and advancement toward Phase 2 dosing in IgAN patients expected in Q3 2026.
View raw filing on EDGAR →FTI Consulting held its 2026 Annual Meeting of Shareholders on June 3, 2026, with voting results on three proposals: election of eight directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation.
View raw filing on EDGAR →The Board authorized an additional $370.0 million share repurchase authorization on June 3, 2026, bringing the aggregate authorization to $2.6 billion, signaling management's confidence in the stock's valuation and the company's financial position.
View raw filing on EDGAR →MBX Biosciences held its 2026 Annual Meeting on June 4, 2026, at which stockholders approved the election of two Class II directors (Patrick J. Heron and Edward T. Mathers) for three-year terms and ratified Ernst & Young LLP as the company's independent auditor.
View raw filing on EDGAR →The company announced a registered direct offering of 7,500,000 common shares for $15 million in aggregate gross proceeds. This is a material equity issuance that dilutes existing shareholders and signals capital-raising activity, characteristic of a dilutive_issuance event. The pricing and share count are explicitly disclosed, indicating a completed or priced offering.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from PMV Pharmaceuticals' June 4, 2026 Annual Meeting. The filing reports voting outcomes on three proposals: election of Class III directors (David H. Mack and Laurie Stelzer), non-binding advisory approval of named executive officer compensation, and ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (FOR, AGAINST, WITHHELD, ABSTAIN, BROKER NON-VOTE) are the hallmark of shareholder meeting result disclosures and are material to investors assessing governance and board composition.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from the June 4, 2026 annual meeting, covering three proposals: election of Class I directors (Joshua E. Schechter and Jill H. Bright), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The filing explicitly states voting tallies for each proposal, which is the hallmark of Item 5.07 shareholder_vote_results disclosures.
View raw filing on EDGAR →The Company entered into a Transaction Support Agreement with debtholders that establishes a conditional equity conversion mechanism whereby noteholders may convert $98.5 million in 2027 PIK Notes into 80–95% of the Company's fully diluted equity upon an Event of Default or after December 31, 2027, representing a potential material change of control.
View raw filing on EDGAR →Dominion Energy entered into an underwriting agreement on June 3, 2026 for the sale of $825 million in senior notes due 2036. While this is a material debt issuance that would affect investor assessment of the company's capital structure and leverage, it does not fit cleanly into the more specific event categories (it is not a dilutive equity issuance, M&A activity, or a financial covenant breach). The disclosure is material as it represents a significant financing transaction, but the taxonomy lacks a dedicated "debt issuance" category.
View raw filing on EDGAR →Reid Hoffman, a Board member since 2017, informed Microsoft on June 2, 2026 that he will not stand for re-election at the 2026 annual shareholder meeting. Although he will remain in office until the Annual Meeting, the principal disclosed action is his departure from the Board. Board-level departures at major public companies are material to investors assessing governance and continuity.
View raw filing on EDGAR →The filing discloses multiple unregistered private placements of equity securities to accredited investors and independent directors under Section 4(a)(2) and Regulation D Rule 506(c), totaling approximately $1.58 million in aggregate proceeds across Class E, Class A-I, and Class A-II common stock. This is a classic dilutive issuance disclosure under Item 3.02, material to investors assessing ownership dilution and capital-raising activity.
View raw filing on EDGAR →The filing discloses a press release announcing a monthly cash distribution to unitholders, filed under Item 2.02 (Results of Operations and Financial Condition). While this is a routine distribution announcement rather than a full earnings release, it is material to unitholders as it communicates the registrant's cash generation and distribution capacity. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with earnings-related disclosures.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from GTJ REIT's Annual Meeting of Stockholders held on June 4, 2026, covering the election of three Class II directors (Paul Cooper, Louis Sheinker, and Stanley Perla) and ratification of Baker Tilly US, LLP as independent auditor. The filing directly matches Item 5.07 requirements and presents vote tallies for each proposal, making this a textbook shareholder_vote_results event that is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →Goldman Sachs Real Estate Finance Trust renewed its advisory agreement with Goldman Sachs Asset Management, L.P. for an additional one-year period effective June 10, 2026, continuing the existing advisory relationship with no substantive changes to terms.
View raw filing on EDGAR →The company completed an unregistered private placement of Class I and Class S common stock totaling approximately $10.8 million in aggregate consideration pursuant to Section 4(a)(2) and Regulation D, diluting existing shareholders' ownership.
View raw filing on EDGAR →The company disclosed routine monthly distributions to shareholders and two significant loan originations totaling $186 million in new mortgage lending activity: a $53.0 million Durham Multifamily loan and a $133.0 million Chicago Multifamily loan, representing material operational activity for the real estate finance trust.
View raw filing on EDGAR →Fortress Net Lease REIT issued and sold approximately 10.9 million common shares for gross proceeds of $113.6 million on June 1, 2026, pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions from registration.
View raw filing on EDGAR →Fortress Net Lease REIT declared distributions on May 29, 2026, with varying net distributions per share across six share classes ranging from $0.0547 to $0.0729 gross, affecting shareholder returns.
View raw filing on EDGAR →Fortress Credit Realty Income Trust completed an unregistered sale of 994,813 common shares across multiple share classes for approximately $20.0 million in gross proceeds, conducted pursuant to Section 4(a)(2), Regulation D, and/or Regulation S exemptions.
View raw filing on EDGAR →The filing discloses an unregistered sale of 613,712 common shares of beneficial interest for approximately $12.6 million under Section 4(a)(2) and Regulation D Rule 506. This is a classic dilutive private placement by a non-traded REIT raising capital through exempt offerings, which materially affects shareholder equity and voting power.
View raw filing on EDGAR →Assembly Biosciences held its Annual Meeting of Stockholders on June 4, 2026, with shareholders voting on five proposals: election of nine directors, advisory vote on named executive officer compensation, ratification of Ernst & Young LLP as auditor, and approval of amendments to the 2018 Stock Incentive Plan and ESPP to increase reserved shares.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder meeting results held on June 3, 2026. The filing reports voting outcomes on four proposals: election of 11 directors, advisory vote on executive compensation, ratification of Deloitte & Touche LLP as auditor, and a shareholder proposal on written consent rights. The detailed vote tallies (For, Against, Abstentions, Broker Non-Votes) for each proposal are the core content of the filing.
View raw filing on EDGAR →The disclosure centers on the Board's approval and grant of 4,060,000 performance share units to Daniel Tassé, the CEO, pursuant to the newly adopted DBV Technologies 2026 Performance Share Unit Plan. This is a compensatory arrangement for a named executive officer involving equity grants with performance and employment conditions, which is the core subject matter of Item 5.02(e). While the filing also references shareholder authorization and plan adoption, the principal disclosed action is the grant of PSUs to the CEO, making this an executive compensation event that would materially affect investor assessment of the company's incentive structure and CEO alignment.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from Cardinal Infrastructure Group's 2026 Annual Meeting of Stockholders held on June 5, 2026. The filing reports the results of two proposals: (1) election of six directors with detailed vote tallies for each nominee, and (2) ratification of Grant Thornton LLP as independent auditor. Item 5.07 explicitly requires disclosure of shareholder vote results, and all directors and the auditor were approved by substantial majorities, making this a material governance event.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure of shareholder vote results from the Annual Meeting of Shareholders held on June 3, 2026. The filing presents detailed voting tallies for three proposals: (i) election of ten directors, (ii) ratification of Deloitte & Touche LLP as independent auditor, and (iii) advisory vote on named executive officer compensation. All three proposals passed with substantial majorities, making this a material disclosure of governance outcomes that investors rely upon to assess board composition and audit oversight.
View raw filing on EDGAR →Mark A. Alexander's resignation from the Board of Directors of Builders FirstSource, Inc., effective immediately on June 3, 2026, constitutes a director departure. The filing explicitly states the resignation was due to health reasons and clarifies there was no disagreement with the Company. Director changes are material events affecting the composition and governance of the registrant.
View raw filing on EDGAR →The Board approved base salaries and target bonuses for four named executive officers (CEO, CFO, CTO, COO) following the company's business combination closing. This is a compensatory arrangement disclosure under Item 5.02(e), establishing initial compensation structures with specific salary amounts and bonus percentages. The disclosure is material as it establishes executive compensation post-merger and would affect investor assessment of the company's cost structure and executive incentives.
View raw filing on EDGAR →This is a clear disclosure of shareholder voting results from McGrath RentCorp's June 3, 2026 annual meeting, covering four proposals: director elections, stock incentive plan amendment, auditor ratification, and executive compensation approval. The filing presents vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal, which is the defining characteristic of Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →The Company terminated three material financing arrangements totaling approximately $57.8 million, including elimination of $56.0 million in term debt, a convertible note indenture, and an equity line, representing a significant restructuring of the Company's capital structure and financial obligations.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Outset Medical's Annual Meeting of Stockholders held on June 4, 2026. The filing presents voting results for three proposals: election of Class III directors (Brent D. Lang and Karen Prange), advisory approval of named executive officer compensation, and ratification of KPMG LLP as independent auditor. All three proposals passed with clear majorities, and the disclosure includes vote counts (For, Against, Abstain, Broker Non-Votes) for each matter.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the results of Definitive Healthcare's 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing presents voting results for four proposals: election of three Class II directors, ratification of Deloitte & Touche LLP as independent auditor, approval of a 15-million-share increase to the 2021 Equity Incentive Plan, and an advisory vote on named executive officer compensation. All proposals passed with substantial majorities, and the disclosure includes detailed vote tallies (For/Against/Abstain/Broker Non-Votes) for each proposal as required by SEC rules.
View raw filing on EDGAR →BrightSpring entered into an underwriting agreement for a secondary offering of 14,999,771 shares at $58.75/share by existing stockholders (KKR Phoenix Aggregator and Management Selling Stockholders), with the Company repurchasing 1,026,465 shares. While this is technically a secondary offering (not a primary issuance by the Company), the Company's share repurchase activity and the substantial equity transaction involving ~15 million shares would materially affect investor assessment of capital structure and ownership dilution.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Sana Biotechnology's 2026 annual meeting held on June 4, 2026. The filing reports voting outcomes for two proposals: (1) election of Class II directors (Hans E. Bishop, Robert Nelsen, and Alise S. Reicin, M.D.) and (2) ratification of Ernst & Young LLP as independent auditor. The detailed vote tallies (For, Against/Withheld, Abstain, and Broker Non-Votes) are presented in tabular form, which is the standard format for Item 5.07 shareholder vote results disclosures.
View raw filing on EDGAR →Gladstone Capital entered into an underwriting agreement on June 3, 2026, for a registered direct offering of $60.0 million in 7.000% Notes due 2029, with closing on June 5, 2026. While this is technically a debt issuance rather than an equity issuance, the disclosure is material to investors as it represents a significant capital raise that increases the company's leverage and financial obligations. The company intends to use proceeds to repay credit facility debt and fund investments, which affects the capital structure and investor risk profile. This is classified as dilutive_issuance as the closest match in the taxonomy for material capital-raising activities, though the event could also be characterized as a material debt financing under other_material.
View raw filing on EDGAR →FMC Corporation completed a $1.2 billion private offering of senior secured notes on June 5, 2026, a material financing transaction intended to refinance existing debt and support general corporate purposes.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from Sight Sciences' June 4, 2026 annual meeting of stockholders. The filing reports voting outcomes for two proposals: election of two Class II directors (Gerhard Burbach and Staffan Encrantz) and ratification of Deloitte & Touche LLP as independent auditor. The disclosure includes vote tallies, quorum information (76.2% attendance), and explicit statement that both proposals passed. This is a textbook Item 5.07 shareholder vote results disclosure, material to investors as it confirms board composition and auditor appointment.
View raw filing on EDGAR →This is a clear disclosure of shareholder vote results from KinderCare's 2026 Annual Meeting of Stockholders held on June 4, 2026. The filing reports voting outcomes on three proposals: election of directors (Michael Nuzzo, John T. Wyatt, and Jean Desravines), ratification of PwC as independent auditor, and advisory approval of named executive officer compensation. All proposals passed with substantial majorities, and the disclosure includes vote tallies (For/Against/Withhold/Abstain/Broker Non-Votes) for each matter, which is the hallmark of Item 5.07 shareholder vote results reporting.
View raw filing on EDGAR →This is a clear Item 5.07 disclosure of shareholder vote results from Harmonic Inc.'s 2026 Annual Meeting held on June 4, 2026. The filing reports voting outcomes on five matters: election of seven directors, advisory approval of named executive officer compensation, frequency of future say-on-pay votes, amendment to the 2025 Equity Incentive Plan, and ratification of Ernst & Young LLP as independent auditor. All matters were approved by stockholders. This is material as it reflects stockholder governance decisions and approval of executive compensation and equity plan amendments.
View raw filing on EDGAR →3D Systems completed a registered public offering of 16.4 million shares at $3.05 per share, raising approximately $50 million in gross proceeds, with an additional 2.5 million share overallotment option granted to underwriters. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and equity base.
View raw filing on EDGAR →